LVM Capital Management Ltd. MI Purchases 1,008 Shares of Eli Lilly and Company (NYSE:LLY)

LVM Capital Management Ltd. MI lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,570 shares of the company's stock after acquiring an additional 1,008 shares during the quarter. Eli Lilly and Company makes up about 4.6% of LVM Capital Management Ltd. MI's holdings, making the stock its 4th biggest holding. LVM Capital Management Ltd. MI's holdings in Eli Lilly and Company were worth $40,940,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Lantz Financial LLC lifted its stake in Eli Lilly and Company by 10.2% in the 1st quarter. Lantz Financial LLC now owns 1,886 shares of the company's stock worth $1,558,000 after acquiring an additional 175 shares in the last quarter. BTC Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 13.7% in the first quarter. BTC Capital Management Inc. now owns 10,502 shares of the company's stock worth $8,675,000 after purchasing an additional 1,265 shares in the last quarter. Andrew Hill Investment Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $2,906,000. Legacy Financial Strategies LLC lifted its position in Eli Lilly and Company by 6.3% in the 1st quarter. Legacy Financial Strategies LLC now owns 728 shares of the company's stock worth $602,000 after buying an additional 43 shares in the last quarter. Finally, Rothschild Investment LLC lifted its position in Eli Lilly and Company by 5.4% in the 1st quarter. Rothschild Investment LLC now owns 10,392 shares of the company's stock worth $8,583,000 after buying an additional 533 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY traded up $15.76 during midday trading on Friday, reaching $738.33. The company's stock had a trading volume of 6,102,436 shares, compared to its average volume of 3,639,718. The stock has a market cap of $699.74 billion, a P/E ratio of 63.05, a PEG ratio of 1.40 and a beta of 0.48. The company has a fifty day simple moving average of $776.85 and a 200 day simple moving average of $799.96. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company's revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.58 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.81%. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. Finally, Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.